期刊文献+

10个前景看好的实验性抗癌药

Ten promising cancer drugs
下载PDF
导出
摘要 抗癌药研究开发是一个热点。本综述对美国知名医药信息机构Fierce Biotech推介的10个后期开发的抗癌药作简要介绍。其中多半安全性和疗效数据有竞争性,新药申请在即,或已经取得获准所需的肯定的后期试验数据;有些则是肿瘤药物开发新领域的代表。 The R&D of cancer drugs is a hot spot. In this review, top 10 late-stage cancer drugs recommended by Fierce Biotech are described. Most of them have competitive safety and efficacy data. New Drug Application (NDA) will be expected in 2012 or positive late-state trial data for approval will be available. Some of them are representative of an emerging area in cancer drug development.
出处 《上海医药》 CAS 2013年第3期55-60,共6页 Shanghai Medical & Pharmaceutical Journal
关键词 实验性药物 抗癌药 结肠直肠癌 甲状腺癌 多发性骨髓瘤 前列腺癌 慢性髓性白血病 黑色素瘤 乳腺癌 肾细胞癌 experimental meds cancer drugs colorectal cancer thyroid cancer multiple myeloma prostate cancer chronic myeloid leukemia melanoma breast cancer renal cell carcinoma
  • 相关文献

参考文献5

  • 1Mullard A.Next-generation proteasome blockers promise safer cancer therapy[].Nature Medicine.2012
  • 2S.M. Wilhelm,J. Dumas,L. Adnane.Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity[].International Journal of Cancer.2011
  • 3Almeida MQ,Hoff AO.Recent advances in the molecular pathogenesis and targeted therapies of medullary thyroid carcinoma[].Current Opinion in Oncology.2012
  • 4Dasmahapatra G,Lembersky D,Son MP,et al.Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC-and ABC-DLBCL cells in vitro and in vivo[].Molecular Cancer Therapeutics.2012
  • 5Mross K,Frost A,Steinbild S,et al.A phase I dose-escalation study of regorafenib(bay73-4506),an inhibitor of oncogenic,angiogenic and stromal kinases,in patients with advanced solid tumors[].Clinical Cancer Research.2012

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部